New Treatment Under Investigation to Determine if Hypertension Can Be Controlled

Minneapolis Heart Institute Foundation® (MHIF) is the First in the Midwest to Test a Procedure That May Lower Blood Pressure.

Hypertension, or high blood pressure, is known as the “silent killer” because it frequently exists with no symptoms or warnings, and it can lead to heart or vascular disease, among other conditions. Currently there are 1 billion people worldwide who have hypertension, and that number is expected to rise to 1.5 billion within a few years. Patients who are diagnosed can try managing the condition through diet and exercise, and there are also a number of medications that can help. However, medications don’t work or are not tolerated for a growing subset of patients, which puts them at greater risk of serious complications.

The Minneapolis Heart Institute Foundation (MHIF) is the first group in the Midwest to work on a study for an investigational device from ReCor Medical Inc. that focuses on the nerves around the renal (kidney) arteries, which may be overactive in patients with hypertension. The RADIANCE-HTN clinical study involves the use of an investigational procedure called the Paradise Renal Denervation System, a minimally invasive procedure that places a small, flexible catheter into the renal arteries leading to the kidneys, then delivers ultrasound energy to the tissues around the renal arteries to decrease over-activity of the nerves. The goal of the study is to investigate whether the Paradise Renal Denervation System can lead to improved blood pressure control in patients who have not been able to control their blood pressure through medications alone; or in patients who are interested in a potential alternative to medication.

MHIF is looking for patients with resistant hypertension or with a recent diagnosis of hypertension to take part in the study. Potential study participants who are between the ages of 18 and 75 years, believe they have healthy kidneys, would be willing to change and/or stop their blood pressure medications for several months under the guidance of a physician, and are willing to make frequent hospital visits to have their blood pressure checked could be eligible to become part of the study.

“The Radiance HTN study may offer us further insight into the mechanism of hypertension and its management,” said Dr. Wang. “It may also determine the potential benefits of this therapy in patients who are early and later in the disease process. Most importantly, it may offer an option for patients who may not have other options.”

For more information about the study or participating in it, contact Rose Peterson, RN at or 612-863-6051, or Sarah Dennis, RN at or 612-863-6257, or visit

About the Minneapolis Heart Institute Foundation®

The Minneapolis Heart Institute Foundation (MHIF) strives to create a world without heart and vascular disease. To achieve this bold vision, it is dedicated to improving the cardiovascular health of individuals and communities through innovative research and education.

  • Scientific Innovation and Research — MHIF is a recognized research leader in the broadest range of cardiovascular medicine and population health initiatives. Each year MHIF leads more than 175 active research projects and publishes more than 120 peer-reviewed studies. Cardiologists, hospitals and communities around the world adopt MHIF protocols to save lives, improve care and create healthier living opportunities.
  • Education and Outreach — MHIF provides more than 10,000 hours of education each year putting its research into practice to improve outcomes. And, MHIF leads cutting-edge, transformative population health research to connect, engage, inform and empower individuals and communities to improve their health.

The Minneapolis Heart Institute Foundation’s work is funded by generous donors and sponsors and supports research initiatives of Minneapolis Heart Institute® at Abbott Northwestern Hospital. Minneapolis Heart Institute® physicians provide care for patients at Abbott Northwestern Hospital in Minneapolis and at 38 community sites across Minnesota and western Wisconsin.

About ReCor Medical, Inc.

ReCor Medical is a private, venture-backed medical device company offering a proprietary ultrasound ablation system for renal denervation (RDN). RDN is being investigated as a promising new potential therapeutic option for treatment of hypertension, one of the most prevalent global medical conditions. The CE-marked Paradise System employs intravascular catheters to denervate the renal nerves by combining the protection of water-based cooling of the renal artery with high intensity ultrasound energy for circumferential renal nerve ablation. The Paradise System has been studied in 3 clinical trials, and has been used in over 200 patients. For additional information visit

For more information about ReCor Medical, please visit The Paradise® System is approved for sale in Europe; it is not approved for sale in the United States.